Dual-listed cancer diagnostics company Pacific Edge has increased its net losses by 37% to $27 million in the year ending March 31, 2023 as it invests to drive growth in its core United States market.
The Dunedin-based company, which uses genetic biomarkers in urine to detect the presence of bladder
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
